Latest Biotech News

Argenica Therapeutics faces a clinical hold from the US FDA on its stroke drug trial application, though its Australian Phase 2 study remains unaffected and on track.

Genetic Technologies Limited has signed binding term sheets to acquire Ellerfield Wealth and Walker Capital, marking a strategic shift into wealth management backed by a $7.8 million valuation and pending ASX approvals.

Nyrada has secured ethics approval to amend its Phase I clinical trial protocol for Xolatryp, allowing testing of higher doses and extended infusion times. This strategic move aims to refine dosing ahead of Phase II trials, with final Phase I results expected by September 2025.

AdAlta Limited has successfully raised $1.1 million through a renounceable rights issue, positioning itself to advance key CAR-T licensing and immunotherapy projects. The capital injection underscores confidence from leadership and investors amid a transformative phase for the biotech company.

EVE Health Group has initiated stability testing for its novel oral treatments targeting erectile dysfunction and dysmenorrhea, marking a crucial step toward regulatory approval in Australia. The company also finalizes its acquisition of Nextract, the developer behind these innovative formulations.

Amplia Therapeutics reports strong progress in its pancreatic cancer drug development, completing the ACCENT trial recruitment ahead of schedule and initiating a new US trial, while managing a $6.57 million loss for FY25.

Noxopharm has secured ethics approval to commence the HERACLES trial, marking the first human study of its novel SOF-SKN™ drug aimed at chronic inflammatory diseases.

INOVIQ Limited clarifies recent share price movements, confirming no undisclosed material information while highlighting an imminent ASCO presentation and provisional patent application tied to its EXO-OC ovarian cancer test.

OncoSil Medical has launched a $8.7 million capital raising via a Share Purchase Plan and Placement, seeking shareholder approval for options issuance and a 400:1 share consolidation.

PYC Therapeutics has secured approval to escalate dosing in its Phase 1a trial of PYC-003 for Polycystic Kidney Disease, moving closer to patient dosing later this year.

Argenica Therapeutics has expanded its intellectual property with a new US patent targeting surgically induced strokes, enhancing the commercial potential of its lead drug candidate ARG-007.

Island Pharmaceuticals has raised $3.6 million through a strategic share placement to advance its lead antiviral drug ISLA-101’s clinical development and broaden its asset portfolio ahead of pivotal Phase 2a/b trial results.